News for Burning Rock Biotech Limited (BNR)

**media[503285]**

GUANGZHOU, China, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited ( BNR, the ”œCompany” or ”œBurning Rock”), a company focusing on the ap

**media[482834]**

GUANGZHOU, China, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited ( BNR, the ”œCompany” or ”œBurning Rock”), a company focused on the app

GUANGZHOU, China, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited ( BNR, the ”œCompany” or ”œBurning Rock”), a company focusing on the ap

**media[481881]**

Guardant Health, Inc. (GH), a prominent player in the liquid biopsy field, experienced a significant share price drop of 5.00%. Currently trading at $20.54 with

Shares of Aehr Test Systems, Inc. AEHR rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial result...

NMPA Grants Marketing Approval to the First Co-Developed NGS-Based Companion Diagnostic for Lung Cancer in China

Burning Rock Announces Changes to Management and Board of Directors

Worldwide Liquid Biopsy (LBx) Market Forecasted to Grow at 29% p.a., Reaching $10.1B by 2029 “ Market Report by DeciBio Consulting LLC

Westford, June 26, 2024 (GLOBE NEWSWIRE) -- SkyQuest projects that the Genetic Testing Market will attain a value of USD 36.40 billion by 2031, with a...

The cancer-screening products maker is in danger of being forcibly delisted due to its sinking stock price.

Key Takeaways: Burning Rock announced its shares could be delisted due to prolonged trading below the required $1 threshold The cancer detection specialist’s former biggest revenue source tumbled 40.6% in the third quarter amid an industry crackdown, spotlighting a major risk for Chinese companies By Doug Young

Key Takeaways: New Horizon Health posted a 61.3 million yuan adjusted profit in the first half of 2023, benefiting from soaring revenue for its three approved products The company sees big growth potential for its home-based cervical cancer screening product By Molly Wen

Key Takeaways: Burning Rock’s net loss narrowed 29% to 185 million yuan in the first quarter from the same period a year earlier, helped by lower R&D and sales expenses Revenues from R&D services for drug companies more than doubled, becoming the company’s latest growth engine By Molly Wen

Burning Rock’s net loss narrowed 29% to 185 million yuan in the first quarter from the same period a year earlier, helped by lower R&D and sales expenses.

GUANGZHOU, China, March 28, 2023 -- Burning Rock Biotech Limited , a company focused on the application of next generation sequencing technology in the field of precision oncology, today... | March 28, 2023

According to Fortune Business Insights™, the US Genetic Testing Market size is expected to reach USD 10.29 Billion by 2027, at a CAGR of 13.0% during the...